The treatment of the elderly multiple myeloma patients

References

• Wingo P A, Ries L A, Rosenberg H M, Miller D S, Edwards B K. Cancer incidence and mortality, 1973-1995: A report card for the U.S. Cancer 1998; 82: 1197–1207
   PubMed Web of Science ®Google Scholar
• Ries L AG, Eisner M P, Kosary C L, et al. SEER Cancer Statistics Review, 1975-2000. National Cancer Institute, Bethesda
   Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin D M. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon 2004, IARC CancerBase No. 5 version 2.0
   Google Scholar
• Phekoo K J, Schey S A, Richards M A, Bevan D H, Bell S, Gillett D, Moller H, Consultant Haematologists, South Thames Haematology Specialist Committee. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127: 299–304
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A, Witzig T E, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33
   PubMed Web of Science ®Google Scholar
• Blade J, Munoz M, Fontanillas M, et al. Treatment of multiple myeloma in elderly people: Long-term results in 178 patients. Age Ageing 1996; 25: 357–361
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Prince H M. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma 2005; 46: 951–966
   PubMed Web of Science ®Google Scholar
• Alexanian R, Haut A, Khan A U, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680–1685
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists' Cooperative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832–3842
   PubMed Web of Science ®Google Scholar
• Crowley J, Jacobson J, Alexanian R. Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience. Semin Hematol 2001; 38: 203–208
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8–11
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M A, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890
   PubMed Web of Science ®Google Scholar
• Segeren C M, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127–130
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003; 14: 1039–1044
   PubMed Web of Science ®Google Scholar
• Cook G, Clark R E, Morris T C, et al. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. Br J Haematol 2004; 126: 792–798
   PubMed Web of Science ®Google Scholar
• Hernandez J M, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004; 127: 159–164
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J Y, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292–1298
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Hernandez J, Sureda A, et al. Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. Hematol Oncol 2006; 24: 205–211
   PubMed Web of Science ®Google Scholar
• Fritz E, Ludwig H. Interferon-α treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000; 11: 1427–1436
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020–1034
   PubMed Web of Science ®Google Scholar
• Berenson J R, Crowley J J, Grogan T M, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168
   PubMed Web of Science ®Google Scholar
• Gulbrandsen N, Hjermstad M J, Wisloff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004; 72: 172–180
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Fietz T, Rieger K, Dimeo F, Blau I W, Thiel E, Knauf W U. Stem cell mobilization in multiple myeloma patients: Do we need an age-adjusted regimen for the elderly?. J Clin Apher 2004; 19: 202–207
   PubMed Web of Science ®Google Scholar
• Morris C L, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: Influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413–423
   PubMed Web of Science ®Google Scholar
• Prince H M, Imrie K, Sutherland D R, et al. Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 1996; 93: 142–145
   PubMed Web of Science ®Google Scholar
• Clavio M, Casciaro S, Gatti A M, et al. Multiple myeloma in the elderly: Clinical features and response to treatment in 113 patients. Haematologica 1996; 81: 238–244
   PubMed Web of Science ®Google Scholar
• Cohen H J, Bartolucci A. Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. Am J Med 1985; 79: 316–324
   PubMed Web of Science ®Google Scholar
• Siegel D S, Desikan K R, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533–539
   PubMed Web of Science ®Google Scholar
• Reece D E, Bredeson C, Perez W S, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplant 2003; 32: 1135–1143
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (≥65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917–922
   PubMed Web of Science ®Google Scholar
• Lenhoff S, Hjorth M, Westin J, et al. Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006; 133: 389–396
   PubMed Web of Science ®Google Scholar
• Dumontet C, Ketterer N, Espinouse D, et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 1998; 21: 1037–1041
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607
   PubMed Web of Science ®Google Scholar
• Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Bertola A, et al. Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). Leukemia 2004; 18: 133–138
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci M T, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 2004; 104: 3052–3057
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. ASCO Meeting Abstr 2006; 24: 1
   Google Scholar
• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003; 40(4 Suppl 4)3–7
   PubMed Web of Science ®Google Scholar
• Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective therapy for advanced myeloma. Haematologica 2001; 86: 399–403
   PubMed Web of Science ®Google Scholar
• Dimopoulus M A, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination or refractory multiple myeloma. Ann Oncol 2001; 12: 991–995
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Ambrosini M T, et al. Thalidomide plus dexamethasone is an effective salvage regimen for multiple myeloma relapsing after autologous transplant. Eur J Haematol 2005; 75: 391–395
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Falco P, et al. Efficacy of low dose thalidomide as first salvage regimen in multiple myeloma. Hemat J 2004; 5: 218–224
   Google Scholar
• Schutt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: Serum level of soluble interleukin 2 receptor as a predictive factor for response rate and survival. Ann Hematol 2005; 84: 594–600
   PubMed Web of Science ®Google Scholar
• Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodelling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969–1976
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: A prospective, multicenter, phase II study. Haematologica 2006; 91: 133–136
   PubMed Web of Science ®Google Scholar
• Offidani M, Covatta L, Marconi M, et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 2004; 5: 312–317
   PubMedGoogle Scholar
• Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006; 76: 273–277
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Elson P, Trebisky B, Karam M A, Hussein M A. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002; 19: 219–226
   PubMed Web of Science ®Google Scholar
• Hussein M A, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81: 889–895
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Gonzalez-Porras J R, Hernandez J M, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863
   PubMed Web of Science ®Google Scholar
• Kropff M H, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCTD) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607–616
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Thomson K, D'Sa S, et al. Low dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Hematol 2005; 129: 763–770
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regiment for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117
   PubMedGoogle Scholar
• Dingli D, Rajkumar S V, Nowakowski G S, et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: A phase II trial. Haematologica 2005; 90: 1650–1654
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Ludwig H, Drach J, Tóthová E, et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. Blood (Suppl.) 2005; 106: 782, ASH Annual Meeting Abstracts
   Google Scholar
• Morgan G J, Krishnan B, Jenner M, Davies F E. Advances in oral therapy for multiple myeloma. Lancet Oncol 2006; 7: 316–325
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367(9513)825–831
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol (Suppl.) 2006; 24(18S)1, ASCO Annual Meeting Proceedings, Part I
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Piersantelli M N, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159–2164
   PubMed Web of Science ®Google Scholar
• Williams C D, Byrne J L, Sidra G, et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone achieves a high response rate in patients with newly diagnosed, VAD-refractory and relapsed myeloma. ASH Annual Meeting Abstracts. Blood (Suppl.) 2004; 104, abstract 1499
   Google Scholar
• Dimopoulos M A, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010). Blood (Suppl.) 2005; 106: 6, ASH Annual Meeting Abstracts
   Google Scholar
• Weber D M, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). J Clin Oncol (Suppl.) 2006; 24(18S)7521, ASCO Annual Meeting Proceedings, Part I
   Google Scholar
• Rajkumar S V, Hayman S R, Lacy M Q, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Benevolo G, et al. Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. ASCO Meeting Abstracts. Blood (Suppl.) 2006; 7518
   Google Scholar
• Richardson P G, Barlogie B, Berenson J, et al. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977–2981
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Ma M H, Yang H H, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chaunhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076
   PubMed Web of Science ®Google Scholar
• Berenson J R, Yang H H, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937–944
   PubMed Web of Science ®Google Scholar
• Orlowski R Z, Voorhees P M, Garcia R A, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065
   PubMed Web of Science ®Google Scholar
• Palumbo A, Ambrosini M T, Benevolo G, et al. Combination of bortezomib, melphalan, prednisone and thalidomide (VMPT) in advanced myeloma: A phase II clinical trial. Haematologica 2006; 185(Suppl 1)
   Google Scholar
• Terpos E, Anagnostopoulos A, Kastritis E, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial. Blood (Suppl.) 2005; 106: 363, ASH Annual Meeting Abstracts
   Google Scholar
• Palumbo A, Avonto I, Bruno B, et al. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. Clin Lymphoma Myeloma 2006; 6: 475–477
   PubMedGoogle Scholar
• Jagannath S, Durie B G, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783
   PubMed Web of Science ®Google Scholar
• Mateos M V, Hernandez J M, Hernandez M T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 2006; 108: 2165–2172
   PubMed Web of Science ®Google Scholar